PubMed · NCBI

Поиск статей PubMed

Ключевые слова, автор, журнал, годы — результаты из PubMed, аннотации с переводом на русский, закладки в браузере.

Найдено: 26 231

Страница 815 из 1000
  1. In Vitro Cell Dev Biol Anim · 2018 · PMID 29700739

    Keynote Symposium.

    Без аннотации

    PubMed ↗
  2. N Engl J Med · 2024 · PMID 38657268

    Specificity of CRISPR-Cas9 Editing in Exagamglogene Autotemcel.

    Yen A, Zappala Z, Fine RS, Majarian TD, Sripakdeevong P, Altshuler D

    Без аннотации

    PubMed ↗
  3. PLoS Pathog · 2016 · PMID 27930735

    Gene Editing Approaches against Viral Infections and Strategy to Prevent Occurrence of Viral Escape.

    White MK, Hu W, Khalili K

    Без аннотации

    PubMed ↗
  4. Genes (Basel) · 2021 · PMID 34828396

    Applications of CRISPR-Cas Technologies to Proteomics.

    Dolgalev G, Poverennaya E

    CRISPR-Cas-based genome editing is a revolutionary approach that has provided an unprecedented investigational power for the life sciences. Rapid and efficient, CRISPR-Cas technologies facilitate the generation of complex biological models and at the same time provide the necessary methods required to study these models in depth. The field of proteomics has already significantly benefited from leveraging the power of CRISPR-Cas technologies, however, many potential applications of these technologies in the context of proteomics remain unexplored. In this review, we intend to provide an introduction to the CRISPR-Cas technologies and demonstrate how they can be applied to solving proteome-centric questions. To achieve this goal, we begin with the description of the modern suite of CRISPR-Cas-based tools, focusing on the more mature CRISPR-Cas9 system. In the second part of this review, we highlight both established and potential applications of the CRISPR-Cas technologies to proteomics.

    PubMed ↗
  5. J Mater Chem B · 2021 · PMID 33942822

    Magnetic nanocomplexes for gene delivery applications.

    Huang RY, Liu ZH, Weng WH, Chang CW

    Gene delivery is an indispensable technique for various biomedical applications such as gene therapy, stem cell engineering and gene editing. Recently, magnetic nanoparticles (MNPs) have received increasing attention for their use in promoting gene delivery efficiency. Under magnetic attraction, gene delivery efficiency using viral or nonviral gene carriers could be universally enhanced. Besides, magnetic nanoparticles could be utilized in magnetic resonance imaging or magnetic hyperthermia therapy, providing extra theranostic opportunities. In this review, recent research integrating MNPs with a viral or nonviral gene vector is summarized from both technical and application perspectives. Applications of MNPs in cutting-edge research technologies, such as biomimetic cell membrane nano-gene carriers, exosome-based gene delivery, cell-based drug delivery systems or CRISPR/Cas9 gene editing, are also discussed.

    PubMed ↗
  6. Epigenetics · 2023 · PMID 36945831

    In vivo DNA methylation editing in zebrafish.

    Liang F, Dong Z, Ye J, Hu W, Bhandari RK, Mai K et al.

    The CRISPR/dCas9-based epigenome editing technique has driven much attention. Fused with a catalytic domain from Dnmt or Tet protein, the CRISPR/dCas9-DnmtCD or -TetCD systems possess the targeted DNA methylation editing ability and have established a series of in vitro and in vivo disease models. However, no publication has been reported on zebrafish (Danio rerio), an important animal model in biomedicine. The present study demonstrated that CRISPR/dCas9-Dnmt7 and -Tet2 catalytic domain fusions could site-specifically edit genomic DNA methylation in vivo in zebrafish and may serve as an efficient toolkit for DNA methylation editing in the zebrafish model.

    PubMed ↗
  7. Mol Ther · 2020 · PMID 32243835

    Variability in Genome Editing Outcomes: Challenges for Research Reproducibility and Clinical Safety.

    Teboul L, Herault Y, Wells S, Qasim W, Pavlovic G

    Genome editing tools have already revolutionized biomedical research and are also expected to have an important impact in the clinic. However, their extensive use in research has revealed much unpredictability, both off and on target, in the outcome of their application. We discuss the challenges associated with this unpredictability, both for research and in the clinic. For the former, an extensive validation of the model is essential. For the latter, potential unpredicted activity does not preclude the use of these tools but requires that molecular evidence to underpin the relevant risk:benefit evaluation is available. Safe and successful clinical application will also depend on the mode of delivery and the cellular context.

    PubMed ↗
  8. Transgenic Res · 2019 · PMID 31321702

    Regulation of genome edited technologies in India.

    Chimata MK, Bharti G

    In India, genetically modified organisms and products thereof are regulated under the "Rules for the manufacture, use, import, export and storage of hazardous microorganisms, genetically engineered organisms or cells, 1989" (referred to as Rules, 1989) notified under the Environment (Protection) Act, 1986. These Rules are implemented by the Ministry of Environment, Forest and Climate Change, Department of Biotechnology and State Governments though six competent authorities. The Rules, 1989 are supported by series of guidelines on contained research, biologics, confined field trials, food safety assessment, environmental risk assessment etc. The definition of genetic engineering in the Rules, 1989 implies that new genome engineering technologies including gene editing technologies like CRISPR/Cas9 and gene drives may be covered under the rules. The regulatory authorities if required, may also review the experiences of other countries in dealing with such new and emerging technologies.

    PubMed ↗
  9. Curr Diabetes Rev · 2024 · PMID 37867274

    Current Landscape of Various Techniques and Methods of Gene Therapy through CRISPR Cas9 along with its Pharmacological and Interventional Therapies in the Treatment of Type 2 Diabetes Mellitus.

    Wal P, Aziz N, Prajapati H, Soni S, Wal A

    BACKGROUND: Type 2 diabetes mellitus (T2DM) is frequently referred to as a "lifestyle illness". In 2000, India (31.7 million) had the greatest global prevalence of diabetes mellitus, followed by China (20.8 million), the United States (17.7 million), and other countries. In recent years, the treatment of gene therapy (T2DM) has attracted intensive interest. OBJECTIVE: We aimed to critically review the literature on the various techniques and methods, which may be a possible novel approach through the gene therapy CRISPR Cas9 and some other gene editing techniques for T2DM. Interventional and pharmacological approaches for the treatment of T2DM were also included to identify novel therapies for its treatment. METHOD: An extensive literature survey was done on databases like PubMed, Elsevier, Science Direct and Springer. CONCLUSION: It can be concluded from the study that recent advancements in gene-editing technologies, such as CRISPR Cas9, have opened new avenues for the development of novel therapeutic approaches for T2DM. CRISPR Cas9 is a powerful tool that enables precise and targeted modifications of the genome.

    PubMed ↗
  10. Trends Biotechnol · 2018 · PMID 30104010

    Angels and Devils: Dilemmas in Dual-Use Biotechnology.

    Getz LJ, Dellaire G

    Dual-use research, which results in knowledge that can be used for both good and ill, has become increasingly accessible in the internet age to both scientists and the general public. Here, we outline some major milestones for dual-use policy and present three vignettes that highlight contemporary dual-use issues in biotechnology.

    PubMed ↗

PubMed отдаёт не больше 10 000 первых результатов — уточните запрос, чтобы увидеть остальные.